For GSK R&D Head Hal Barron 'There's No Place Like Home' For Seeding Innovation
GSK President R&D Hal Barron came to a big investor meeting with one bit of tangible news, a collaboration with consumer genetics leader 23andMe. Barron and CEO Emma Walmsley talked about the deal and Barron's California headquarters in a media briefing.
You may also be interested in...
A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.
AZ's Mene Pangalos and GSK's Hal Barron are at different stages of overseeing culture changes in their respective R&D workforces - but both agreed at a recent conference that such transformations are key for the future viability of their drug companies.
CEO Emma Walmsley has vowed to be more decisive when it comes to progressing drugs to late-stage development. The company terminated five programs, including several in respiratory disease to prioritize other assets and business development.